Ann Coloproctol > Epub ahead of print |
|
Study | Year | Country | Study type | Quality score | No. of patients |
Sex |
BMI (kg/m2) | Laparoscopic (%) | PTP | Study design | Observational period | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | |||||||||||
Lee et al. [19] (cohort A) | 2016 | Korea | Cohort | 22 | 400 | 248 | 152 | 23±3 | 69.8 | Not applicable | All patients had routine duplex US | POD 28 |
Lee et al. [19] (cohort B) | 2016 | Korea | Cohort | 22 | 148 | 79 | 69 | 23±3 | 80.4 | Not applicable | Only symptomatic patients had venous US | POD 28 |
Hata et al. [18] | 2014 | Japan | Cohort | 23 | 619 | 371 | 248 | 22±3 | 67.7 | Fondaparinux 2.5 or 1.5 mg | Only symptomatic patients had duplex US, MDCT, or ascending phlebography for DVT; MDCT, pulmonary scintigraphy, or pulmonary arteriography for PE | 1 Day after use of fondaparinux (4–8 day) |
Nakagawa et al. [20] | 2019 | Japan | RCT | 27 | 116 | 55 | 61 | 22 (17–36)a | 100 | Enoxaparin 20 mg | All patients had routine duplex US | POD 28 |
23 (16–33)a | ||||||||||||
Shukla et al. [21] | 2008 | India | RCT | 16 | 99 | 65 | 34 | 19b | 90.9 | Dalteparin sodium 2,500 IU | All patients had routine duplex US | POD 6/7 |
Tokuhara et al. [22] | 2017 | Japan | Cohort | 20 | 119 | 78 | 50c | 22 (16–30)c | 100 | Fondaparinux 2.5 or 1.5 mg | Patients with a D-dimer score greater than 1 μg/mL on day 2 and day 7 postoperative underwent duplex US | POD 10 |
Yang et al. [24] | 2011 | Korea | Cohort | 19 | 3,645 | 2,294 | 1,351 | NRd | NR | Enoxaparin 20 mg subcutaneous only to high-risk patients | Only symptomatic patients had duplex US or contrast venography for DVT; CT scan, ventilation-perfusion scan for PE | NR |
Yamashita et al. [23] | 2021 | Japan | Cohort | 21 | 187 | 123 | 93c | NRc,e | 87.2 | Intravenous heparin 10,000 IU and enoxaparin 2,000 U subcutaneous | Only symptomatic patients had duplex US | POD 29 |
Values are presented as number only, mean±standard deviation, or median (interquartile range).
BMI, body mass index; PTP, pharmacological thromboprophylaxis; POD, postoperative day; US, ultrasonography; MDCT, multidetector computed tomography; DVT, deep vein thrombosis; PE, pulmonary embolism; RCT, randomized controlled trial; NR, not recorded; CT, computed tomography.